An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: A multi-center study of 381 patients

Haematologica

Volumn 93, Issue 11, 2008, Pages 1734-1738

  Nahi, Hareth ^a   Hägglund, Hans ^a   Ahlgren, Thomas ^b   Bernell, Per ^a   Hardling, Mats ^c   Karlsson, Karin ^b   Lazarevic, Vladimir Lj ^d   Linderholm, Mats ^e   Smedmyr, Bengt ^f   Åström, Maria ^g   Hallböök, Helene ^f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

9p21; Leukemia; p14ARF; p53

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL RATE;

EID: 55549115330     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13227     Document Type: Article

References (21)

1. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 2000;27:540-59.
2. Mancini M, Scappaticci D, Cimino G Nanni M, Derme V, Elia L, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005; 105:3434-41.
3. Heyman M, Grandér D, Bröndum-Nielsen K, Liu Y, Söderhäll S, Einhorn S. Deletions of the short arm of chromosome 9, including the interferon-α/-β genes, in acute lymphocytic leukemia. Studies on loss of heterozygosity, parental origin of deleted genes and prognosis. Int J Cancer 1993;54:748-53.
4. Heerema NA, Sather HN, Sensel MG Liu-Mares W, Lange BJ, Bostrom BC, et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 1999;94:1537-44.
5. Martin TG, Gajewski JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Hematol Oncol Clin North Am 2001;15:97-120.
6. Thiebaut A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000;14:1353-66.
7. Gupta V, Yi QL, Brandwein J, Minden MD, Schuh AC, Wells RA, et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant 2004;33:397-404.
8. Schauer P, Arlin ZA, Mertelsmann R, Cirrincione C, Friedman A, Gee TS, et al. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol 1983;1:462-70.
9. Hallböök H, Hägglund H, Stockelberg D, Nilsson PG, Karlsson K, Björkholm M, et al. Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience. Swedish Adult ALL Group. Bone Marrow Transplant 2005;35:1141-8.
10. Hallböök H, Simonsson B, Ahlgren T, Björkholm M, Carneskog J, Grimfors G, et al. High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. Br J Haematol 2002;118:748-54.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
12. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Blood 2007;109:3189-97.
13. Kowalczyk J, Sandberg AA. A possible subgroup of ALL with 9p. Cancer Genet Cytogenet 1983;9:383-5.
14. Diaz MO, Rubin CM, Harden A, Ziemin S, Larson RA, Le Beau MM, et al. Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med 1990;322:77-82.
15. Siebert R, Willers CP, Schramm A, Fosså A, Dresen IM, Uppenkamp M, et al. Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines. Br J Haematol 1995;91:350-4.
16. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
17. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, et al. p14ARF links the tumour suppressors RB and p53. Nature 1998;395:124-5.
18. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. Embo J 2001;20:1331-40.
19. Omura-Minamisawa M, Diccianni MB, Batova A, Chang RC, Bridgeman LJ, Yu J, et al. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia. Clin Cancer Res 2000;6:1219-28.
20. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
21. Schmitz NM, Hirt A, Aebi M, Leibundgut K. Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia. Am J Pathol 2006;169:1074-9.